Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Under Armour Inc Class A trades at $4.79 (market cap $2.08B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.3× Under Armour Inc Class A's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Under Armour Inc Class A for 99 Days on average.
| TVTX | UAA | |
|---|---|---|
Market Cap | $4.88B | $2.08B |
Volume | 1,668,577 | 7,012,020 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $8.14 |
52-Week Low | $26.79 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $5.01B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Under Armour (UAA) trades at $4.79, down 2.84% on the day, amid mixed signals. The stock shows a bullish technical trend but faces fundamental headwinds with a net loss of $201.27M in 2025 and negative profit margins. Recent news highlights the company's focus on product simplification and margin recovery despite revenue weakness, with Q1 2027 earnings beating estimates but revenue falling short.
The outlook is cautious; while cost discipline supports margins, persistent revenue declines and negative cash flow pose risks. Analyst consensus is a 'Hold' with a $5.79 price target, suggesting limited upside. Investors should weigh margin improvements against top-line challenges and high short interest, which could lead to volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
